Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
By Abdo A. Elfiky. Life Science, 2020
628 citations recorded by the source corpus.
Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). Materials and methods In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. Significance The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
Subfields: Computational Theory and Mathematics, General Health Professions, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/363d105f439431ae40539b573f657a63da9d764d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
In Infectious Diseases
Citations in the corpus
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro (2020, neutral): “tial antivirals for SARS-CoV-2 with alternative mechanisms of action (Dong et al., 2020; Elfiky, 2020; Gordon et al., 2020; Li and De Clercq, 2020; Wang et al., 2020) would thus be important as soon as practicable.”
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study (2020, neutral): “(Doublie and Ellenberger, 1998 , Elfiky, 2020a , Elfiky and Ismail, 2018 .”
- Cardiovascular complications in COVID-19 (2020, neutral): “Current medications under study include antivirals (e.g., remdesivir, ribavirin, lopinavir/ritonavir, favipiravir), antimalarials (e.g., chloroquine, hydroxychloroquine), azithromycin, corticosteroids, and biologics (tocilizumab) [4, [40] [41] [42] .”
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic (2020, neutral): “A number of SARS-related coronaviruses have been discovered in bats, and a working theory is that bats may have been the initial zoonotic host for SARS-CoV-2 given that its genome is 96.2% identical to a bat coronavirus (8).”
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective (2020, positive): “Four compounds derived from IDX-184 have proved its potency against Zika and Hepatitis C Viruses, and two compounds possess a low binding affinity to RdRp (Cinnamaldehyde and Thymoquinone) are used as negative controls (Elfiky, 2017, 2019; 2020b; Elfiky & Ismail, 2017; 2018; 2019).”